Project Grant R01AI202797
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $949K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $423,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate bacteriophage interactions with nontuberculous mycobacteria in mammalian cell intracellular environments. The research addresses the therapeutic use of bacteriophages—naturally occurring viruses that infect and kill bacteria—as an alternative treatment for drug-resistant nontuberculous...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,229,998 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel TH17-inducing mucosal tuberculosis vaccine. The research advances preclinical development of NETB-EA, a nanoemulsion-based vaccine candidate that delivers immunodominant Mycobacterium tuberculosis antigens (AG85B and ESAT6) via intranasal vaccination to induce T helper type 17 cell...
- The National Institute of Allergy and Infectious Diseases awarded $490,704 to the Trustees of Tufts College (doing business as Tufts University School of Medicine) on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop spatial multi-omics methodology predicting granuloma trajectory and bacterial restriction during tuberculosis vaccination. The recipient will use spatial proteomic and transcriptional profiling to map immune cell infiltrates in...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $1,296,750 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel trivalent adjuvanted tuberculosis vaccine. The research will characterize and advance a trivalent TB vaccine candidate consisting of three antigens—PPE20 (RV1387), ESXG (RV0287), and...
- The National Institute of Allergy and Infectious Diseases awarded $1.59 million to the University of Colorado-Denver under Project Grant R01AI187511 on September 17, 2025, to support research integrating genomic architecture and tuberculosis immunity in Africa under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research generates population-level genetic data (HLA, KIR, and SNP array) on 5,000 case/control samples from multi-ancestry individuals in South Africa's...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $460,625 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune mechanisms underlying BCG vaccine protection against tuberculosis. The research uses Collaborative Cross mouse strains to identify immune signatures associated with vaccine-induced TB protection across genetically diverse host populations. The study focuses on a...
- The National Institute of Allergy and Infectious Diseases awarded Colorado State University $2,036,679 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct high-throughput screening and characterization of small-molecule inhibitors targeting N-terminal autoproteolysis of coronavirus main protease precursors. The recipient will develop and execute cell-based assays to identify compounds that selectively interfere with precursor-mediated...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $717,003 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and assess protective mRNA vaccines against tuberculosis. The project focuses on evaluating the safety, immunogenicity, and protective efficacy of QRNA, a novel mRNA vaccine delivered via QUILA-DOTAP (QTAP), a lipid nanoparticle adjuvant designed for stable mRNA delivery across...
- The National Institute of Allergy and Infectious Diseases awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $153,680 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of type 1 interferon signaling in promoting antigen archiving and vaccine stability within lymphatic endothelial cells. Lymphatic endothelial cells serve as the first point of contact for antigens and...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $865,432 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the mechanisms of action of saponin combination adjuvants for vaccine development. The award funds research into saponin/monophosphoryl lipid A nanoparticles (SMNP), cage-like nanostructures that combine saponins derived from the Chilean soapbark tree with a Toll-like receptor-4 agonist. The...